Hepion Pharmaceuticals(HEPA)

Search documents
Hepion Pharmaceuticals(HEPA) - 2023 Q2 - Quarterly Report
2023-08-14 20:12
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 46-2783806 (I.R.S. Employer Identification Number) 399 Thornall Street, First Floor Edison, New Jersey 08837 (Address of Principal Executive Offices) (732) 902-4000 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...
Hepion Pharmaceuticals(HEPA) - 2023 Q1 - Quarterly Report
2023-05-12 20:17
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...
Hepion Pharmaceuticals(HEPA) - 2022 Q4 - Annual Report
2023-04-10 20:51
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware (State or other jurisdiction of incorporation or organization) 46-2783806 (I.R.S. Employer Identification Number) 399 Thornall Street, First Floor Edison, New Jersey 08837 For the year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...
Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
2020-10-31 00:10
| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|---------------------------------------------------------------------------------|------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Our AI-Driven Bioinformatics Platform is | | | | | | | Accelerating the Development of a Novel NASH Therapeutic and Creating Pathways | to Opti ...
Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
2019-09-17 05:43
1 Nasdaq: HEPA theplon PHARMACEUTICALS CORPORATE PRESENTATION • 2019 Nasdaq: HEPA Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that co ...